Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. - Wikidata - awgldk - TriplyDB

Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers.

Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers.

http://www.wikidata.org/entity/Q39134104

about

From animal models to human disease: a genetic approach for personalized medicine in ALS Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS).SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice.Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.Profilin 1 with the amyotrophic lateral sclerosis associated mutation T109M displays unaltered actin binding and does not affect the actin cytoskeleton.Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis.MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease.A serum microRNA signature for amyotrophic lateral sclersosis reveals convergent RNA processing defects and identifies presymptomatic mutation carriers.Circulating microRNAs in Neurodegenerative Diseases.Differential Expression of Several miRNAs and the Host Genes AATK and DNM2 in Leukocytes of Sporadic ALS Patients.Exploring microRNA Biomarker for Amyotrophic Lateral Sclerosis.Macro roles for microRNAs in neurodegenerative diseases Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis Preclinical progression of neurodegenerative diseases

P2860

Q26741250-B6138744-50FE-4550-B2C7-E4F2794B2D2E Q33755664-ACD1FA24-F463-4128-8941-8FD14907E565 Q35115920-94ED279D-C644-4F11-B5F7-F711E36F7B6F Q35828632-9FE75DDF-8A48-40CF-8BBF-A184FCC1F5E9 Q35842667-B5B002F8-66F6-44D5-8DE4-D916B06946F0 Q36601006-0F562825-EC0F-49E4-A65F-07764E2F71DC Q39250013-CB330459-390B-4C4C-9AB7-BDD420A51B03 Q47767334-298A842A-7BBC-4E13-89D8-197173E3DED1 Q48475699-A32BB6EA-D1F6-433A-9099-FE1F5A9E19B0 Q48713195-D46B1D86-A348-4D60-A6FE-61D61899FB98 Q52579274-B234A3D6-E13F-4A28-8E29-89BAA875F684 Q55282282-824E7430-E873-49E1-A29A-A462E4A0F524 Q57174024-BB43209E-4732-4A1B-898C-2C7387C1E2BF Q58698224-E53540BC-BEFA-4066-BB48-4BADE26A299D Q58804706-21639573-E92D-4729-9F18-0C9EE2C24108

P2860

Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers.

http://www.wikidata.org/entity/Q39134104

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Serum microRNAs in patients wi ...... re-manifest mutation carriers.

@en

Serum microRNAs in patients wi ...... re-manifest mutation carriers.

@nl

type

label

Serum microRNAs in patients wi ...... re-manifest mutation carriers.

@en

Serum microRNAs in patients wi ...... re-manifest mutation carriers.

@nl

prefLabel

Serum microRNAs in patients wi ...... re-manifest mutation carriers.

@en

Serum microRNAs in patients wi ...... re-manifest mutation carriers.

@nl

P1433

Q39134104-B71E397A-5EB5-438B-8260-4B998799FCE5

P1476

Q39134104-E7A2D9E0-A06A-4C40-A99B-568632A8380F

P2093

Q39134104-179DE354-A3FB-4677-95FC-AAAA40072E09

Q39134104-50212D93-864C-4207-806B-B10DC114EB9A

Q39134104-50DA2E93-020B-4721-AC56-61B02081B1D0

Q39134104-5571F016-CA22-4123-85C4-6CACA27DB06A

Q39134104-732BB018-BC24-4BD4-B7B5-E5A811F66669

Q39134104-9CD0788C-280D-4BDD-9E82-FFA7B91A546C

Q39134104-9F3D7210-B043-4853-BAAF-82048816FDFC

Q39134104-A6B51809-6526-4DDA-B7F1-7B5ADF01D86E

Q39134104-BD365891-CC89-4E3A-8BED-E3716BC9EBE0

Q39134104-BF590E5B-2177-4BBD-B079-727C2BF6A652

P2860

Q39134104-02C22CAF-0FFC-49A6-BD07-CF5D31025C1C

Q39134104-040C638A-0232-4546-AA0B-FB578A0D7FCC

Q39134104-048E2531-7C06-4CDF-849C-400B7186F51A

Q39134104-0544D0F5-A1A8-4D5B-9A58-3397BE855B39

Q39134104-062BB17E-C0F4-412D-B58B-017E4B826618

Q39134104-0762C2DF-FFFD-4211-8F70-8ECF6B4B8066

Q39134104-0B46F947-23BF-4F0F-9EBA-E2CAB6CD62E8

Q39134104-0BB7845C-51B2-45F0-B076-F9FD2B276899

Q39134104-0CE9DFCA-D122-42CD-8BBF-75C5DDFE9770

Q39134104-13BF2B8A-1082-4366-AAC2-43C17250EB51

P304

Q39134104-D05E2B93-2934-414F-98B4-8DE2DCDCFD50

P31

Q39134104-7795FFE9-7E24-4455-A909-49E800C40DE9

P356

Q39134104-ECE7AB68-FED7-4007-ADDD-BF690F4F0148

P407

Q39134104-30EF288F-DE09-495E-BBE3-3F262E980BF5

P433

Q39134104-C50CC5DD-0008-40BC-B7B8-4D301145A9AF

P478

Q39134104-2D97BF16-1EE1-4015-822D-B858D1DE65A6

P50

Q39134104-A50FBA08-85FD-4F22-813D-FAF5B61A30B4

Q39134104-F4A90BE6-9C95-4800-AFC8-784EFB02B191

P577

Q39134104-8A69BB95-80D9-4D8B-8326-027A80F73504

P5875

Q39134104-D34D6426-51A3-4B37-8952-76A689F635AD

P698

Q39134104-32EEEF7F-FA0F-4283-88BC-88310BE36AAD

P921

Q39134104-612A6472-98FC-4593-9802-1C91FFC4F638

Q39134104-696AE9EC-95E8-42EE-9AFB-C47F32904C37

P356

P1433

P1476

Serum microRNAs in patients wi ...... re-manifest mutation carriers.

@en

P2093

Alexander E Volk

http://www.w3.org/2001/XMLSchema#string

Anže Lošdorfer Božič

http://www.w3.org/2001/XMLSchema#string

Axel Freischmidt

http://www.w3.org/2001/XMLSchema#string

Benjamin Mayer

http://www.w3.org/2001/XMLSchema#string

Christine A F von Arnim

http://www.w3.org/2001/XMLSchema#string

Christoph Dieterich

http://www.w3.org/2001/XMLSchema#string

Jochen H Weishaupt

http://www.w3.org/2001/XMLSchema#string

Karin M Danzer

http://www.w3.org/2001/XMLSchema#string

Karlheinz Holzmann

http://www.w3.org/2001/XMLSchema#string

Kathrin Müller

http://www.w3.org/2001/XMLSchema#string

P2860

Trash or Treasure: extracellular microRNAs and cell-to-cell communication

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS

FUS stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment

DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4)

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study

Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis

Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

P304

2938-2950

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWU249

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 11

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Albert C Ludolph

Peter M Andersen

P577

2014-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265394615

http://www.w3.org/2001/XMLSchema#string

P698

25193138

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis